Open AccessLong-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor
Author(s) -
Borys Hrinczenko,
Nicholas Iannotti,
Sanjay Goel,
David R. Spigel,
Howard Safran,
Matthew H. Taylor,
Jaafar Bennouna,
Deborah J. Wong,
Karen Kelly,
Claire F. Verschraegen,
Marcis Bajars,
Juliane Manitz,
Mary Ruisi,
James L. Gulley
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0930
Subject(s) - javelin , avelumab , medicine , oncology , term (time) , lung cancer , solid tumor , cancer , immunotherapy , nivolumab , mechanical engineering , engineering , throwing , physics , quantum mechanics
Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and exploratory descriptive analyses were conducted. Results: Individuals with varying baseline characteristics who had received up to 6 years of avelumab were reviewed. Overall, 37/340 (10.9%) had received ≥2 years of treatment; in this subgroup, best response was complete response in 5.4%, partial response in 59.5% and stable disease in 29.7%; 51.4% had continued treatment beyond disease progression. Conclusions: In this study, 11% of patients with advanced non-small-cell lung cancer received ≥2 years of avelumab treatment and experienced prolonged response or continued clinical benefit. Clinical Trial Registration: NCT02395172 ( ClinicalTrials.gov )